171 related articles for article (PubMed ID: 3346839)
1. Characterization of muscarinic cholinergic receptor subtypes in human peripheral lung.
Bloom JW; Halonen M; Yamamura HI
J Pharmacol Exp Ther; 1988 Feb; 244(2):625-32. PubMed ID: 3346839
[TBL] [Abstract][Full Text] [Related]
2. Characterization of high affinity [3H]pirenzepine and (-)-[3H] quinuclidinyl benzilate binding to muscarinic cholinergic receptors in rabbit peripheral lung.
Bloom JW; Halonen M; Lawrence LJ; Rould E; Seaver NA; Yamamura HI
J Pharmacol Exp Ther; 1987 Jan; 240(1):51-8. PubMed ID: 3806397
[TBL] [Abstract][Full Text] [Related]
3. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes.
Watson M; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 1986 May; 237(2):419-27. PubMed ID: 3754581
[TBL] [Abstract][Full Text] [Related]
4. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes.
Watson M; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1986 May; 237(2):411-8. PubMed ID: 3754580
[TBL] [Abstract][Full Text] [Related]
5. Solubilization with digitonin alters the kinetics of pirenzepine binding to muscarinic receptors from rat forebrain and heart.
Wang JX; Mei L; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1987 Sep; 242(3):981-90. PubMed ID: 3116203
[TBL] [Abstract][Full Text] [Related]
6. Muscarinic cholinergic receptor binding sites differentiated by their affinity for pirenzepine do not interconvert.
Gil DW; Wolfe BB
J Pharmacol Exp Ther; 1986 May; 237(2):577-82. PubMed ID: 3009794
[TBL] [Abstract][Full Text] [Related]
7. Characterization of [3H]pirenzepine binding to muscarinic cholinergic receptors solubilized from rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1985 Jul; 234(1):37-44. PubMed ID: 3839265
[TBL] [Abstract][Full Text] [Related]
8. Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1984 Mar; 228(3):648-55. PubMed ID: 6546770
[TBL] [Abstract][Full Text] [Related]
9. Characterization of muscarinic receptor subtypes on human peripheral lung.
Casale TB; Ecklund P
J Appl Physiol (1985); 1988 Aug; 65(2):594-600. PubMed ID: 3170410
[TBL] [Abstract][Full Text] [Related]
10. [3H]Pirenzepine and [3H]quinuclidinyl benzilate binding to brain muscarinic cholinergic receptors. Differences in measured receptor density are not explained by differences in receptor isomerization.
Luthin GR; Wolfe BB
Mol Pharmacol; 1984 Sep; 26(2):164-9. PubMed ID: 6548291
[TBL] [Abstract][Full Text] [Related]
11. Differential ontogeny of putative M1 and M2 muscarinic receptor binding sites in the murine cerebral cortex and heart.
Evans RA; Watson M; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1985 Dec; 235(3):612-8. PubMed ID: 3841156
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic characterization and functional role of muscarinic autoreceptors in the rabbit striatum.
James MK; Cubeddu LX
J Pharmacol Exp Ther; 1987 Jan; 240(1):203-15. PubMed ID: 3806384
[TBL] [Abstract][Full Text] [Related]
13. Antagonists and agonists interactions with the muscarinic receptor of the rat large airways.
Scott T; McMahon KK
J Pharmacol Exp Ther; 1988 Oct; 247(1):136-42. PubMed ID: 3171971
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to a synthetic peptide can be used to distinguish between muscarinic acetylcholine receptor binding sites in brain and heart.
Luthin GR; Harkness J; Artymyshyn RP; Wolfe BB
Mol Pharmacol; 1988 Sep; 34(3):327-33. PubMed ID: 3419425
[TBL] [Abstract][Full Text] [Related]
15. On the muscarinic receptors in the urinary bladder and the putative subclassification of muscarinic receptors.
Nilvebrant L
Acta Pharmacol Toxicol (Copenh); 1986; 59 Suppl 1():1-45. PubMed ID: 3524114
[TBL] [Abstract][Full Text] [Related]
16. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes.
Burke RE
Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217
[TBL] [Abstract][Full Text] [Related]
17. Species difference in the muscarinic receptors of thoracic aorta.
Yamanaka K; Hashimoto S; Muramatsu I
J Pharmacol Exp Ther; 1986 Jun; 237(3):980-6. PubMed ID: 3754896
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of binding of muscarinic receptor antagonists in rat brain homogenates.
Lee JH; el-Fakahany EE
J Pharmacol Exp Ther; 1985 Jun; 233(3):707-14. PubMed ID: 3839264
[TBL] [Abstract][Full Text] [Related]
19. A unique regulatory profile and regional distribution of [3H]pirenzepine binding in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes.
Watson M; Yamamura HI; Roeske WR
Life Sci; 1983 Jun; 32(26):3001-11. PubMed ID: 6688111
[TBL] [Abstract][Full Text] [Related]
20. High affinity binding of [3H]acetylcholine to muscarinic receptors. Regional distribution and modulation by guanine nucleotides.
Gurwitz D; Kloog Y; Sokolovsky M
Mol Pharmacol; 1985 Sep; 28(3):297-305. PubMed ID: 4033630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
